Methylphenidate self-administration and conditioned place preference in an animal model of attention-deficit hyperactivity disorder: The spontaneously hypertensive rat

Behavioural Pharmacology

Volumn 22, Issue 1, 2011, Pages 31-39

  Peńa, Ike C Dela ^a   Ahn, Hyung Seok ^a   Choi, Ji Young ^a   Shin, Chan Young ^b   Ryu, Jong Hoon ^c   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Konkuk University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

Attention deficit hyperactivity disorder; Conditioned place preference; Methylphenidate; Reinforcement; Reward; Self administration; Spontaneously hypertensive rat; Wistar rat

Indexed keywords

METHYLPHENIDATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DRUG ABUSE; DRUG INFUSION; DRUG SELF ADMINISTRATION; MALE; MOTIVATION; NONHUMAN; PLACE PREFERENCE; PREVALENCE; RAT; REINFORCEMENT; REWARD; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR RAT;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOICE BEHAVIOR; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; MALE; METHYLPHENIDATE; RATS; RATS, INBRED SHR; RATS, WISTAR; SELF ADMINISTRATION;

EID: 78651391664     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328342503a     Document Type: Article

References (83)

1. Adriani W, Laviola G (2003). Elevated levels of impulsivity and reduced place conditioning with d-amphetamine: two behavioral features of adolescence in mice. Behav Neurosci 117:695-703.
2. Adriani W, Laviola G (2004). Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model. Behav Pharmacol 15:341-352.
3. Adriani W, Chiarotti F, Laviola G (1998). Elevated novelty seeking and peculiar d-amphetamine sensitization in periadolescent mice compared with adult mice. Behav Neurosci 112:1152-1166.
4. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders, (4th ed., text rev). Washington, DC: American Psychiatric Association.
5. Amini B, Yang PB, Swann AC, Dafny N (2004). Differential locomotor responses in male rats from three strains to acute methylphenidate. Int J Neurosci 114:1063-1084.
6. Arnett J (1992). Reckless behavior in adolescence: a developmental perspective. Dev Rev 12:339-373.
7. Askenasy EP, Taber KH, Yang PB, Dafny N (2007). Methylphenidate (Ritalin): behavioral studies in the rat. Intern J Neurosci 117:757-794.
8. Babcock Q, Byrne T (2000). Student perceptions of methylphenidate abuse at a public liberal arts college. J Am Coll Health 49:143-145.
9. Bá lint S, Czobor P, Mé szá ros A, Simon V, Bitter I (2008). Neuropsychological impairments in adult attention-deficit hyperactivity disorder: a literature review (in Hungarian). Psychiatr Hung 23:324-335.
10. Bardo MT, Valoney JM, Bevins RA (1999). Locomotion and conditioned place preference produced by acute intravenous amphetamine: role of dopamine receptors and individual differences in amphetamine self-administration. Psychopharmacol (Berl) 143:39-46.
11. Biederman J (1998). Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 59:4-16.
12. Bizot J, Chenault N, Houze B, Herpin A, David S, Pothion S, Troviro F (2007). Methylphenidate reduces impulsive behaviour in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats. Psychopharmacol (berl) 193:215-223.
13. Botly LC, Burton CL, Rizos Z, Fletcher PJ (2008). Characterization of methylphenidate self-administration and reinstatement in the rat. Psychopharmacol (Berl) 199:55-66.
14. Burton CL, Nobrega JN, Fletcher PJ (2010). The effects of adolescent methylphenidate self-administration on responding for a conditioned reward, amphetamine-induced locomotor activity, and neuronal activation. Psyschopharmacol (Berl) 208:455-468.
15. Cailhol S, Mormede P (1999). Strain and sex differences in the locomotor response and behavioral sensitization to cocaine in hyperactive rats. Brain Res 842:200-205.
16. Cloninger CR (1987). Neurogenetic adaptive mechanisms in alcoholism. Science 236:410-416.
17. Cormier E (2008). Attention-deficit/hyperactivity disorder: a review and update. J Pediatr Nurs 23:345-357.
18. Crews F, He J, Hodge C (2007). Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol Biochem Behav 86:189-199.
19. Da Silva GE, Vendruscolo LF, Takahashi RN (2005). Effects of ethanol on locomotor and anxiety-like behaviors and the acquisition of ethanol intake in Lewis and spontaneously hypertensive rats. Life Sci 77:693-706.
20. Elia J, Ambrosini PJ, Rapoport JL (1999). Treatment of attention-deficit hyperactivity disorder. N Engl J Med 340:780-788.
21. Findling RL, Dogin JW (1998). Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry 59:42-49.
22. Foreman DM (2006). Attention-deficit hyperactivity disorder: legal and ethical aspects. Arch Dis Child 91:192-194.
23. Gatley SJ, Pan D, Chen R, Chaturvedi G, Ding YS (1996). Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 58:231-239. (Pubitemid 126352709)
24. Hooks MS, Jones GH, Neill DB, Justice JB (1992). Individual differences in amphetamine sensitization: dose-dependent effects. Pharmacol Biochem Behav 41:203-210.
25. Izenwasser S (2005). Differential effects of psychoactive drugs in adolescents and adults. Crit Rev Neurobiol 17:51-67.
26. Jentsch JD, Taylor JR (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacol 146:373-390.
27. Johansen EB, Sagvolden T (2005). Slower extinction of responses maintained by intracranial self-stimulation (ICSS) in an animal model of attention-deficit hyperactivity disorder (ADHD). Behav Brain Res 162:22-31.
28. Kalivas PW, Pierce RC, Cornish J, Sorg BA (1998). A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol 12:49-53.
29. Klein-Schwartz W, McGrath J (2003). Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Chil Adolesc Psychiatry 42:288-294. (Pubitemid 39592084)
30. Kofalvi A, Fritzsche M (2008). The endocannabinoid system is a major player in schizophrenia. In: Kofalvi A, editor. Cannabinoids and the brain. US: Springer; pp. 458-528.
31. Kollins SH (2003). Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 64:14-18.
32. Kollins SH (2008). ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 12: 115-125.
33. Kollins SH, MacDonald EK, Rush CR (2001). Assessing the abuse potential of methylphenidate in nonhuman and human subjects: review. Pharmacol Biochem Behav 68:611-627.
34. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS (2005). Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8:1470-1477.
35. Kuczenski R, Segal DS (1997). Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037. (Pubitemid 27176139)
36. Lambert NM, Hartsough CS (1998). Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 31:533-544.
37. Laviola G,Wood RD, Kuhn C, Francis R, Spear LP (1995). Cocaine sensitization in periadolescent and adult rats. J Pharmacol Exp Ther 275:345-357.
38. Leonard BE, McCartan D,White J, King DJ (2004). Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 19:151-180.
39. Macri S, AdrianiW, Chiarotti F, Laviola G (2002). Risk taking during exploration of a plus-maze is greater in adolescent than in juvenile or adult mice. Anim Behav 64:541-546.
40. Mahajaran P, Mahajaran V, Ravagnan G, Paino G (2001). The weaver mutant mouse: a model to study the ontogeny of dopamine transmission systems and their role in drug addiction. Prog Neurobiol 64:269-276.
41. Martin-Iverson MT, Ortmann R, Fibiger HC (1985). Place preference conditioning with methylphenidate and nomifensine. Brain Res 332:59-67.
42. Marusich J, Bardo M (2009). Differences in impulsivity on a delay-discounting task predict self-administration of a low unit dose of methylphenidate in rats. Behav Pharmacol 20:447-454.
43. Marusich JA, Beckmann JS, Gipson CD, Bardo MT (2010). Methylphenidate as a reinforcer for rats: contingent delivery and intake escalation. Exp Clin Psychopharmacol 8:257-266.
44. Mayes R, Bagwell C, Erkulwater J (2008). ADHD and the rise in stimulant use among children. Harv Rev Psychiatry 16:151-166.
45. Meririnne E, Kankaanpaa A, Seppala T (2001). Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2-receptor antagonists. J Pharmacol Exp Ther 298:539-550.
46. Mithani S, Martin-Iverson MT, Phillips AG, Fibiger HC (1986). The effects of haloperidol on amphetamine- and methylphenidate-induced conditioned place preferences and locomotor activity. Psychopharmacol (Berl) 90:247-252.
47. Nielsen JA, Duda NJ, Mokler DJ, Moore KE (1984). Self-administration of central stimulants by rats: a comparison of the effects of d-amphetamine, methylphenidate and McNeil 4612. Pharmacol Biochem Behav 20:227-232.
48. Ohlmeier MD, Peters K, Te Wildt BT (2008). Comorbidity of alcohol and substance dependence with attention-deficit/hyperactivity disorder (ADHD). Alcohol Alcohol 43:300-304.
49. Pandolfo P, Pamplona F, Prediger R, Takahashi R (2007). Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by cannabinoid receptor agonist WIN 55,212-2. Eur J Pharmacol 563:141-148.
50. Pandolfo P, Vendruscolo L, Sordi R, Takahashi R (2009). Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder. Psychopharmacol (Berl) 205:319-326.
51. Papa M, Diewald L, Carey MP, Eposito FJ, Gironi Carnevale UA, Sadile AG (2002). A rostro-caudal dissociation in the dorsal and ventral striatum of the juvenile SHR suggests an anterior hypo- and a posterior hyperfunctioning mesocorticolimbic system. Behav Brain Res 130:171-179.
52. Piazza PV, Deminière JM, Le Moal M, Simon H (1989). Factors that predict individual vulnerability to amphetamine self-administration. Science 245: 1511-1513.
53. Rappley MD (1997). Safety issues in the use of methylphenidate: an American perspective. Drug Saf 17:143-148.
54. Riddle EL, Fleckenstein AE, Hanson GR (2005). Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7:E847-E851.
55. Sagvolden T (2000). Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 24:31-39.
56. Sagvolden T, Metzger MA, Schiorbeck HK, Rugland AL, Spinnangr I, Sagvolden G (1992). The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforces and to psychomotor stimulants. Behav Neural Biol 58:103-112.
57. Sagvolden T, Johansen EB, Aase H, Russell VA (2005). A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 28:397-419; discussion 419-468.
58. Schubiner H (2005). Substance abuse in patients with attention-deficit hyperactivity disorder: therapeutic implications. CNS Drugs 19:643-655.
59. Segal DS, Kuczenski R (1987). Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 242:917-926.
60. Sonuga-Barke EJ (2005). Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry 57:1231-1238.
61. Spear LP, Brake SC (1983). Periadolescence age: age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol 16:83-109.
62. Sullivan MA, Rudnik-Levin F (2001). Attention deficit/hyperactivity and substance abuse: diagnostic and therapeutic considerations. Ann NY Acad Sci 931:251-270.
63. Swanson J, McBurnett K, Christian D, Wigal T (1995.) Stimulant medications and the treatment of children with ADHD. In: Ollendick T, Prinz R, editors. Advances in clinical psychology. New York, NY: Plenum Press; pp. 265-322.
64. Teicher MH, Andersen SL, Hostetter JC Jr (1995). Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Brain Res Dev Brain Res 89:167-172.
65. Tsai CF, Lin MT (1988). Locomotor hyperactivity in hypertensive rats. Pharmacol 36:27-34.
66. Tzschentke TM (2007). Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12:227-462.
67. Vendruscolo LF, Izi GS, Takahashi RN, Ramos A (2008). Chronic methylphenidate treatment during adolescence increases anxiety-related behaviors and ethanol drinking in adult spontaneously hypertensive rats. Behav Pharmacol 19:21-27.
68. Vendruscolo LF, Izidio GS, Takahashi RN (2009). Drug reinforcement in a rat model of attention deficit/hyperactivity disorder-the spontaneously hypertensive rat (SHR). Curr Drug Abuse Rev 2:177-183.
69. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. (1995). Is MPH like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52:456-463.
70. Volkow ND, Fowler JS,Wang GJ (1999). Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 13:337-345.
71. Volkow ND,Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. (2001). Therapeutic doses of oral MPH significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121.
72. Wender PH (1998). Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 59:76-79.
73. White FJ, Kalivas PW (1998). Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51:141-153.
74. Whitehorn D, Atwater DG, Low WC, Gellis JE, Hendley ED (1983). Independence of blood pressure and locomotor hyperactivity in normotensive and genetically hypertensive rat. Behav Neural Biol 37:357-361.
75. Wilens TE, Kwon A, Tanguay S, Chase R, Moore H, Faraone SV, et al. (2005). Characteristics of adults with attention deficit hyperactivity disorder plus substance use disorder: the role of psychiatric comorbidity. Am J Addict 14:319-327.
76. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. (2008). Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47:21-31.
77. Wise RA, Bozarth MA (1987). A psychomotor stimulant theory of addiction. Psychol Rev 94:469-492.
78. Witt ED (1994). Mechanisms of alcohol abuse and alcoholism in adolescents: a case for developing animal models. Behav Neural Biol 62:168-177.
79. Wooters TE, Dwoskin LP, Bardo MT (2006). Age and sex differences in the locomotor effect of repeated methylphenidate in rats classified as high or low novelty responders. Psychopharmacol (Berl) 188:18-27.
80. Yang P, Behrang A, Swann A, Nachum D (2003). Strain differences in the behavioral responses of male rats to chronically administered MPH. Brain Res 971:139-152.
81. Yang PB, Swann AC, Dafny N (2006). Acute and chronic methylphenidate doseresponse assessment on three adolescent male rat strains. Brain Res Bull 71:301-310.
82. Zakharova E, Wade D, Izenwasser S (2009). Sensitivity to cocaine conditioned reward depends on sex and age. Pharmacol Biochem Behav 92:131-134.
83. Zakharova E, Leoni G, Kichko I, Izenwasser S (2009). Differential effects of methamphetamine and cocaine on conditioned place preference and locomotor activity in adult and adolescent male rats. Behav Brain Res 198:45-50.